Immune reconstitution after cord blood transplantation: Peculiarities, clinical implications and management strategies

Cytotherapy

Volumn 17, Issue 6, 2015, Pages 711-722

  Lucchini, Giovanna ^a   Perales, Miguel Angel ^b   Veys, Paul ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Immune reconstitution; Serotherapy; Stem cell transplantation; T cells; Thymic function; Umbilical cord blood; Viral infections

Indexed keywords

CYCLOSPORIN; CYTOKINE; MYCOPHENOLATE MOFETIL;

ARTICLE; B LYMPHOCYTE; CELL HOMING; CLINICAL EFFECTIVENESS; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; ENGRAFTMENT; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFECTION RISK; NATURAL KILLER CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STEM CELL EXPANSION; T CELL DEPLETION; THERAPY EFFECT; THYMUS FUNCTION; TREATMENT RESPONSE; VIRUS INFECTION; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; METABOLISM; TRANSPLANTATION;

CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINES; FETAL BLOOD; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84928992844     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.03.614     Document Type: Article

References (107)

1. Small T.N., Papadopoulos E.B., Boulad F., Black P., Castro-Malaspina H., Childs B.H., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999, 93:467-480.
2. Storek J., Gooley T., Witherspoon R.P., Sullivan K.M., Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997, 54:131-138.
3. Storek J., Joseph A., Espino G., Dawson M.A., Douek D.C., Sullivan K.M., et al. Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood 2001, 98:3505-3512.
4. Storek J., Witherspoon R.P., Storb R. Tcell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995, 16:413-415.
5. Sauter C., Abboud M., Jia X., Heller G., Gonzales A.M., Lubin M., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011, 17:1460-1471.
6. Servais S., Lengline E., Porcher R., Carmagnat M., Peffault de Latour R., Robin M., et al. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:507-517.
7. Maraninchi D., Gluckman E., Blaise D., Guyotat D., Rio B., Pico J.L., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987, 2:175-178.
8. Curtis R.E., Rowlings P.A., Deeg H.J., Shriner D.A., Socie G., Travis L.B., et al. Solid cancers after bone marrow transplantation. NEngl J Med 1997, 336:897-904.
9. Barker J.N., Byam C.E., Kernan N.A., Lee S.S., Hawke R.M., Doshi K.A., et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 2010, 16:1541-1548.
10. Rubinstein P., Carrier C., Scaradavou A., Kurtzberg J., Adamson J., Migliaccio A.R., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. NEngl J Med 1998, 339:1565-1577.
11. Laughlin M.J., Barker J., Bambach B., Koc O.N., Rizzieri D.A., Wagner J.E., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. NEngl J Med 2001, 344:1815-1822.
12. Szabolcs P., Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007, 9:111-122.
13. Rocha V., Cornish J., Sievers E.L., Filipovich A., Locatelli F., Peters C., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
14. Wagner J.E., Barker J.N., DeFor T.E., Baker K.S., Blazar B.R., Eide C., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
15. Rocha V., Labopin M., Sanz G., Arcese W., Schwerdtfeger R., Bosi A., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. NEngl J Med 2004, 351:2276-2285.
16. Niehues T., Rocha V., Filipovich A.H., Chan K.W., Porcher R., Michel G., et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children-a Eurocord analysis. Br J Haematol 2001, 114:42-48.
17. Kanda J., Chiou L.W., Szabolcs P., Sempowski G.D., Rizzieri D.A., Long G.D., et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1664-1676.
18. Wikell H., Ponandai-Srinivasan S., Mattsson J., Gertow J., Uhlin M. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation. Transpl Infect Dis 2014, 16:203-212.
19. Mold J.E., Venkatasubrahmanyam S., Burt T.D., Michaëlsson J., Rivera J.M., Galkina, et al. Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science 2010, 330:1695-1699.
20. Danby R., Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol 2014, 5:1-19.
21. Rocha V., Broxmeyer H.E. New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:S126-S132.
22. Lin S.J., Yan D.C., Lee Y.C., Hsiao H.S., Lee P.T., Liang Y.W., et al. Umbilical cord blood immunology: relevance to stem cell transplantation. Clin Rev Allergy Immunol 2012, 42:45-57.
23. Kim Y.J., Broxmeyer H.E. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol 2011, 79:112-126.
24. Brown J.A., Boussiotis V.A. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008, 127:286-297.
25. Early E., Renn D.J. Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses. Clin Exp Immunol 1999, 116:527-533.
26. Sato K., Nagayama H., Takahashias T.A. Aberrant CD3- and CD28-mediated signaling events in cord blood T cells are associated with dysfunctional regulation of Fas ligand-mediated cytotoxicity. JImmunol 1999, 162:4464-4471.
27. Kaminski B.A., Kadereit S., Miller R.E., Leahy P., Stein K.R., Topa D.A., et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 2003, 102:4608-4617.
28. Seggewiss R., Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010, 115:3861-3868.
29. Derniame S., Lee F., Domogala A., Madrigal A., Saudemont A. Unique effects of mycophenolate mofetil on cord blood T cells: implications for GVHD prophylaxis. Transplantation 2014, 97:870-878.
30. Xu L., Tanaka S., Bonno M., Ido M., Kawai M., Yamamoto H. CB CD4+CD25+ regulatory T cells fail to inhibit cord blood NK cell functions due to insufficient production and expression of TGF-beta 1. Cell Immunol 2014, 290:89-95.
31. Mayer E., Bannert C., Gruber S., Klunker S., Spittler A., Akdis C.A., et al. Cord blood derived CD4+ CD25(high) T cells become functional regulatory T cells upon antigen encounter. PLoS One 2012, 7:e29355.
32. Torelli G.F., Maggio R., Peragine N., Chiaretti S., De Propris M.S., Lucarelli B., et al. Functional analysis and gene expression profile of umbilical cord blood regulatory T cells. Ann Hematol 2012, 91:155-161.
33. Wu L.Y., Blanco A., Cooper M.D., Lawton A.R. Ontogeny of B-lymphocyte differentiation induced by pokeweed mitogen. Clin Immunol Immunopathol 1976, 5:208-217.
34. Kessel A., Yehudai D., Peri R., Pavlotzky E., Bamberger E., Tov N., et al. Increased susceptibility of cord blood B lymphocytes to undergo spontaneous apoptosis. Clin Exp Immunol 2006, 145:563-570.
35. Gaddy J., Broxmeyer H.E. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol 1997, 180:132-142.
36. Verneris M.R., Miller J.S. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol 2009, 147:185-191.
37. Luevano M., Daryouzeh M., Alnabhan R., Querol S., Khakoo S., Madrigal A., et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol 2012, 73:248-257.
38. Drohan L., Harding J.J., Holm B., Cordoba-Tongson E., Dekker C.L., Holmes T., et al. Selective developmental defects of cord blood antigen-presenting cell subsets. Human Immunol 2004, 65:1356-1369.
39. Small T.N., Avigan D., Dupont B., Smith K., Black P., Heller G., et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997, 3:65-75.
40. Powles R., Singhal S., Treleaven J., Kulkarni S., Horton C., Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998, 91:3481-3486.
41. Savani B.N., Mielke S., Rezvani K., Montero A., Yong A.S., Wish L., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1216-1223.
42. Chakrabarti S., Brown J., Guttridge M., Pamphilon D.H., Lankester A., Marks D.I. Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback. Bone Marrow Transplant 2003, 32:23-30.
43. Le Blanc K., Barrett A.J., Schaffer M., Hagglund H., Ljungman P., Ringden O., et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009, 15:1108-1115.
44. Burke M.J., Vogel R.I., Janardan S.K., Brunstein C., Smith A.R., Miller J.S., et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:831-840.
45. Lewin S.R., Heller G., Zhang L., Rodrigues E., Skulsky E., van den Brink M.R., et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002, 100:2235-2242.
46. Weinberg K., Blazar B.R., Wagner J.E., Agura E., Hill B.J., Smogorzewska M., et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001, 97:1458-1466.
47. Maecker H.T. Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 2009, 485:375-391.
48. van Zelm M.C., Szczepanski T., van der Burg M., van Dongen J.J. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. JExp Med 2007, 204:645-655.
49. Lev A., Simon A.J., Bareket M., Bielorai B., Hutt D., Amariglio N., et al. The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG-2-deficient SCID patients. PLoS One 2012, 7:e30494.
50. Charrier E., Cordeiro P., Brito R.M., Mezziani S., Herblot S., Le Deist F., et al. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant 2013, 48:376-382.
51. Jacobson C.A., Turki A.T., McDonough S.M., Stevenson K.E., Kim H.T., Kao G., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:565-574.
52. Renard C., Barlogis V., Mialou V., Galambrun C., Bernoux D., Goutagny M.P., et al. Lymphocytes subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2010, 152:322-330.
53. Oshrine B.R., Li Y., Teachey D.T., Heimall J., Barrett D.M., Bunin N. Comparison of recipients of partially T cell depleted peripheral blood stem cells and umbilical cord blood. Biol Blood Marrow Transplant 2013, 19:1581-1589.
54. Bartelink I.H., Belitser S.V., Knibbe C.A., Danhof M., de Pagter A.J., Egberts T.C., et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 2013, 19:305-313.
55. Clave E., Lisini D., Douay C., Giorgiani G., Busson M., Zecca M., et al. Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse. Front Immunol 2013, 4:1-8.
56. Moretta A., Maccario R., Fagioli F., Giraldi E., Busca A., Montagna D., et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001, 29:371-379.
57. Komanduri K.V., Wieder E.D., Benjamin C.L., Levy R.B. The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression. Immunol Res 2013, 57:140-150.
58. Williams K.M., Hakim F.T., Gress R.E. Tcell immune reconstitution following lymphodepletion. Semin Immunol 2007, 19:318-330.
59. Chiesa R., Gilmour K., Qasim W., Adams S., Worth A.J., Zhan H., et al. Omission of invivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br J Haematol 2012, 156:656-666.
60. Zheng C., Luan Z., Fang J., Sun X., Chen J., Li C.K., et al. Comparison of conditioning regimens with or without antithymocyte globulin for unrelated cord blood transplantation in children with high-risk or advanced hematological malignancies. Biol Blood Marrow Transplant 2015, 21:707-712.
61. Politikos I., Vassiliki A.B. The role of the thymus in T cell immune reconstitution after umbilical cord blood transplantation. Blood 2014, 124:3201-3211.
62. Ruggeri A., Peffault de Latour R., Carmagnat M., Clave E., Douay C., Larghero J., et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis 2011, 13:456-465.
63. Komanduri K.V., St John L.S., de Lima M., McMannis J., Rosinski S., McNiece I., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
64. Clave E., Busson M., Douay C., Peffault de Latour R., Berrou J., Rabian C., et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009, 113:6477-6484.
65. Olkinuora H., von Willebrand E., Kantele J.M., Vainio O., Talvensaari K., Saarinen-Pihkala U., et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. Scand J Immunol 2011, 73:586-593.
66. Krenger W., Hollander G.A. The immunopathology of thymic GVHD. Semin Immunopathol 2008, 30:439-456.
67. Krenger W., Rossi S., Hollander G.A. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation 2000, 69:2190-2193.
68. Krenger W., Rossi S., Piali L., Hollander G.A. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood 2000, 96:347-354.
69. Parkman R., Cohen G., Carter S.L., Weinberg K.I., Masinsin B., Guinan E., et al. Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 2006, 12:919-927.
70. Clave E., Rocha V., Talvensaari K., Busson M., Dolay C., Appert M.L., et al. Prognostic value of pretransplantation host thymic function in HLA-identical sibling hematopoietic stem cell transplantation. Blood 2005, 105:2608-2613.
71. Dahi P.B., Perales M.A., Devlin S.M., Olson A., Lubin M., Gonzales A.M., et al. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplantation. Leuk Lymphoma 2014, 21:1-19.
72. Beck J.C., Wagner J.E., DeFor T.E., Brunstein C.G., Schleiss M.R., Young J.A., et al. Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:15-22.
73. McGoldrick S.M., Bleakley M.E., Guerrero A., Turtle C.J., Yamamoto T.N., Pereira S.E., et al. Cytomegalovirus specific T cells are primed early after cord blood transplant but fail to control virus invivo. Blood 2013, 121:796-803.
74. Brown J.A., Stevenson K., Kim H.T., Cutler C., Ballen K., McDonough S., et al. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 2010, 115:4111-4119.
75. Talvensaari K., Clave E., Douay C., Rabian C., Garderet L., Busson M., et al. Abroad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002, 99:1458-1464.
76. Chapman M., Warren E.H., Wu C.J. Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant 2012, 18:S151-S160.
77. van Heijst J.W., Ceberio I., Lipuma L.B., Samilo D.W., Wasilewski G.D., Gonzales A.M., et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med 2013, 19:372-377.
78. Krell P.F., Reuther S., Fischer U., Keller T., Weber S., Gombert M., et al. Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a beta chain CDR3 sequence associated with hepatitis-induced pathogenesis. Haematologica 2013, 98:1388-1396.
79. Meyer E.H., Hsu A.R., Liliental J., Lohr A., Florek M., Zehnder J.L., et al. Adistinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood 2013, 121:4955-4962.
80. Muraro P.A., Robins H., Malhotra S., Howell M., Phippard D., Desmarais C., et al. Tcell repertoire following autologous stem cell transplantation for multiple sclerosis. JClin Invest 2014, 124:1168-1172.
81. Nakatani K., Imai K., Shigeno M., Sato H., Tezuka M., Okawa T., et al. Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation. Bone Marrow Transplant 2014, 49:1155-1161.
82. Kottaridis P.D., Milligan D.W., Chopra R., Chakraverty R.K., Chakrabarti S., Robinson S., et al. Invivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000, 96:2419-2425.
83. Peggs K.S. Role of MabCampath in allogeneic transplantation. Ann Hematol 2004, 83(Suppl 1):S66-S68.
84. Chakraverty R., Orti G., Roughton M., Shen J., Fielding A., Kottaridis P., et al. Impact of invivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010, 116:3080-3088.
85. Juliusson G., Theorin N., Karlsson K., Frodin U., Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006, 37:503-510.
86. Fehse N., Fehse B., Kroger N., Zabelina T., Freiberger P., Kruger W., et al. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. JHematother Stem Cell Res 2003, 12:237-242.
87. Meijer E., Bloem A.C., Dekker A.W., Verdonck L.F. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation 2003, 75:1910-1913.
88. Terasako K., Sato K., Sato M., Kimura S., Nakasone H., Okuda S., et al. The effect of different ATG preparations on immune recovery after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology 2010, 15:165-169.
89. Hiwarkar P., Gaspar H.B., Gilmour K., Jagani M., Chiesa R., Bennett-Rees N., et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013, 48:803-808.
90. Lindemans C.A., Chiesa R., Amrolia P.J., Rao K., Nikolajeva O., de Wildt A., et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood 2014, 123:126-132.
91. Geyer M.B., Jacobson J.S., Freedman J., George D., Moore V., van de Ven C., et al. Acomparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011, 155:218-234.
92. Devillier R., Harbi S., Fürst S., Crocchiolo R., El-Cheikh J., Castagna L., et al. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation. Biol Blood Marrow Transplant 2014, 20:1560-1565.
93. Morio T., Atsuta Y., Tomizawa D., Nagamura-Inoue T., Kato K., Ariga T., et al. Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan. Br J Haematol 2011, 154:363-372.
94. Parikh S.H., Mendizabal A., Benjamin C.L., Komanduri K.V., Antony J., Petrovic A., et al. Anovel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with non-malignant diseases. Biol Blood Marrow Transplant 2014, 20:326-336.
95. Ponce D.M., Sauter C., Devlin S., Lubin M., Gonzales A.M., Kernan N.A., et al. Anovel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation. Biol Blood Marrow Transplant 2013, 19:799-803.
96. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft-and transplantation-related factors. Br J Haematol 2009, 147:262-274. Eurocord-Netcord Registry; European Blooed and Marrow Transplant Group.
97. Ballen K.K., Spitzer T.R., Yeap B.Y., McAfee S., Dey B.R., Attar E., et al. Double unrelated reduced intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transpl 2007, 13:82-89.
98. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, et al. General and virus specific immune cell reconstitution following double cord transplantation [published online ahead of print February 20, 2015]. Biol Blood Marrow Transpl.
99. Purtill D, Ponce DM, Devlin SM, Lubin MN, Dahi PB, Giralt SA. Day 45 lymphocyte recovery is independently associated with transplant-related mortality after adult myeloablative double-unit cord blood transplantation (dCBT). 56th ASH Meeting Abstract2014.
100. Hanley P., Leen A., Gee A.P., Leung K., Martinez C., Krance R.A., et al. Multi-virus-specific T-cell Therapy for patients after hematopoietic stem cell and cord blood transplantation. Blood 2013, 122. [American Society of Hematology abstract].
101. Barker J.N., Doubrovina E., Sauter C., Jaroscak J.J., Perales M.A., Doubrovin M., et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010, 116:5045-5049.
102. Micklethwaite K.P., Savoldo B., Hanley P.J., Leen A.M., Demmler-Harrison G.J., Cooper L.J., et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010, 115:2695-2703.
103. Delaney C., Bollard C.M., Shpall E.J. Cord blood graft engineering. Biol Blood Marrow Transplant 2013, 19:S74-S78.
104. Rizwan R., Levine J.E., Defor T., Ferarra J.L., Weisdorf D.J., Blazar B.R., et al. Peritransplant palifermin use and lymphocyte recovery after T cell replete, matched related allogeneic hematopoietic cell transplantation. Am J Hematol 2011, 86:879-882.
105. Sportès C., Hakim F.T., Memon S.A., Zhang H., Chua K.S., Brown M.R., et al. Administration of rhIL-7 in humans increases invivo TCR repertoire diversity by preferential expansion of naïve T cell subsets. JExp Med 2008, 205:1701-1714.
106. Perales M.A., Goldberg J.D., Yuan J., Koehne G., Lechner L., Papadopoulos E.B., et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012, 120:4882-4891.
107. Bari S., Kwee Hong Seah K., Poon Z., Man Sze Cheung A., Fan X., Ong S., et al. Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation. Biol Blood Marrow Transplant 2014, [published online ahead of print]. doi:10.1016/j.bbmt.2014.12.022.